<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9188842" created="07/03/31" creator="Yumiko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9188842</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="concomitant_downregulation" sem="Other">Concomitant downregulation</term> of <term id="T2" lex="IgH_3&apos;_enhancer_activity" sem="Other"><term id="T3" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term> activity</term> and <term id="T4" lex="c-myc_expression" sem="Other"><term id="T5" lex="c-myc" sem="DNA_domain_or_region">c-myc</term> expression</term> in a <term id="T6" lex="plasmacytoma_x_fibroblast_environment" sem="Cell_cultured">plasmacytoma x fibroblast environment</term>: implications for dysregulation of translocated <term id="T7" lex="c-myc" sem="DNA_domain_or_region">c-myc</term>.</sentence>
<event KT="Other" id="E1">
<type class="Gene_expression"/>
<theme idref="T5"/>
<clue>Concomitant downregulation of IgH 3&apos; enhancer activity and c-myc <clueType>expression</clueType> <clueLoc>in a plasmacytoma x fibroblast</clueLoc> environment: implications for dysregulation of translocated c-myc.</clue>
</event>
<event KT="Investigation" id="E2">
<type class="Negative_regulation"/>
<theme idref="T3"/>
<clue>Concomitant <clueType>downregulation</clueType> <linkTheme>of</linkTheme> IgH 3&apos; enhancer activity and c-myc expression <clueLoc>in a plasmacytoma x fibroblast</clueLoc> environment: implications for dysregulation of translocated c-myc.</clue>
</event>
<event KT="Investigation" id="E3">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<clue>Concomitant <clueType>downregulation</clueType> <linkTheme>of</linkTheme> IgH 3&apos; enhancer activity and c-myc expression <clueLoc>in a plasmacytoma x fibroblast</clueLoc> environment: implications for dysregulation of translocated c-myc.</clue>
</event>
<event KT="Other" id="E4">
<type class="Localization"/>
<theme idref="T7"/>
<clue>Concomitant downregulation of IgH 3&apos; enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of <clueType>translocated</clueType> c-myc.</clue>
</event>
<event KT="Analysis" id="E5">
<type class="Regulation"/>
<theme idref="E4"/>
<clue>Concomitant downregulation of IgH 3&apos; enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: <clueKT>implications</clueKT> for <clueType>dysregulation</clueType> <linkTheme>of</linkTheme> translocated c-myc.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">Regulation of <term id="T8" lex="immunoglobulin_heavy_chain_(IgH)_gene" sem="DNA_domain_or_region">immunoglobulin heavy chain (IgH) gene</term> expression is controlled by a <term id="T9" lex="B_cell-specific_promoter" sem="DNA_domain_or_region">B cell-specific <term id="A1" sem="DNA_domain_or_region">promoter</term></term>, <term id="T10" lex="intronic_enhancer" sem="DNA_domain_or_region">intronic enhancer</term> and additional <term id="T11" lex="B_cell-specific_enhancer_elements" sem="DNA_domain_or_region">B cell-specific <term id="A2" sem="DNA_domain_or_region">enhancer elements</term></term> identified recently in the 3&apos; end of the <term id="T12" lex="IgH_locus" sem="DNA_domain_or_region">IgH locus</term>.</sentence>
<event KT="Other" id="E6">
<type class="Gene_expression"/>
<theme idref="T8"/>
<clue>Regulation of immunoglobulin heavy chain (IgH) gene <clueType>expression</clueType> is controlled by a B cell-specific promoter, intronic enhancer and additional B cell-specific enhancer elements identified recently in the 3&apos; end of the IgH locus.</clue>
</event>
<event KT="Other" id="E7">
<type class="Regulation"/>
<theme idref="E6"/>
<clue><clueType>Regulation</clueType> <linkTheme>of</linkTheme> immunoglobulin heavy chain (IgH) gene expression is controlled by a B cell-specific promoter, intronic enhancer and additional B cell-specific enhancer elements identified recently in the 3&apos; end of the IgH locus.</clue>
</event>
<event KT="Analysis" Source="Other" id="E8">
<type class="Regulation"/>
<theme idref="E7"/>
<cause idref="A1"/>
<clue>Regulation of immunoglobulin heavy chain (IgH) gene expression is <clueType>controlled</clueType> <linkCause>by</linkCause> a <clueLoc>B cell</clueLoc>-specific promoter, intronic enhancer and additional B cell-specific enhancer elements <clueKT>identified</clueKT> <clueSource>recently</clueSource> in the 3&apos; end of the IgH locus.</clue>
</event>
<event KT="Analysis" Source="Other" id="E9">
<type class="Regulation"/>
<theme idref="E7"/>
<cause idref="A2"/>
<clue>Regulation of immunoglobulin heavy chain (IgH) gene expression is <clueType>controlled</clueType> <linkCause>by</linkCause> a <clueLoc>B cell</clueLoc>-specific promoter, intronic enhancer and additional B cell-specific enhancer elements <clueKT>identified</clueKT> <clueSource>recently</clueSource> in the 3&apos; end of the IgH locus.</clue>
</event>
<event KT="Analysis" Source="Other" id="E10">
<type class="Regulation"/>
<theme idref="E7"/>
<cause idref="T10"/>
<clue>Regulation of immunoglobulin heavy chain (IgH) gene expression is <clueType>controlled</clueType> <linkCause>by</linkCause> a <clueLoc>B cell</clueLoc>-specific promoter, intronic enhancer and additional B cell-specific enhancer elements <clueKT>identified</clueKT> <clueSource>recently</clueSource> in the 3&apos; end of the IgH locus.</clue>
</event>
<sentence id="S3">One of the latter elements, the <term id="T13" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term>, is of particular interest: (1) it is B cell-specific and active only in <term id="T14" lex="late_B_cell_development" sem="Other">late <term id="A3" sem="Cell_natural">B cell</term> development</term>; (2) in <term id="T15" lex="rodent_plasmacytoma" sem="Tissue_natural">rodent plasmacytomas</term> and in some <term id="T16" lex="human_Burkitt&apos;s_lymphoma" sem="Tissue_natural">human Burkitt&apos;s lymphomas</term> it is part of a <term id="T17" lex="locus_control_region" sem="DNA_domain_or_region">locus control region</term> (<term id="T18" lex="LCR" sem="DNA_domain_or_region">LCR</term>) that is involved in deregulation of the <term id="T19" lex="c-myc_oncogene" sem="DNA_domain_or_region"><term id="T20" lex="c-myc" sem="DNA_domain_or_region">c-myc</term> oncogene</term> as a result of translocation into the <term id="T21" lex="IgH_locus" sem="DNA_domain_or_region">IgH locus</term>; and (3) it has been implicated in the mechanisms that control <term id="T22" lex="Ig_gene_class" sem="DNA_family_or_group">Ig gene class</term> switch recombination.</sentence>
<event KT="Other" id="E11">
<type class="Cell_differentiation"/>
<theme idref="A3"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell <clueType>development</clueType>; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Fact" id="E12">
<type class="Positive_regulation"/>
<theme idref="T13"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) <corefTheme>it</corefTheme> is <clueLoc>B cell</clueLoc>-specific and <clueType>active</clueType> only <clueTime>in late B cell development</clueTime>; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Other" Polarity="Negative" id="E13">
<type class="Regulation"/>
<theme idref="T19"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) <clueLoc>in rodent plasmacytomas</clueLoc> and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in <clueType><cluePolarity>deregulation</cluePolarity></clueType> <linkTheme>of</linkTheme> the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Other" Polarity="Negative" id="E130">
<type class="Regulation"/>
<theme idref="T19"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and <clueLoc>in some human Burkitt&apos;s lymphomas</clueLoc> it is part of a locus control region (LCR) that is involved in <clueType><cluePolarity>deregulation</cluePolarity></clueType> <linkTheme>of</linkTheme> the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Fact" id="E14">
<type class="Regulation"/>
<theme idref="E13"/>
<cause idref="T18"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is <clueType>involved</clueType> <linkTheme>in</linkTheme> deregulation of the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Fact" id="E140">
<type class="Regulation"/>
<theme idref="E130"/>
<cause idref="T18"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is <clueType>involved</clueType> <linkTheme>in</linkTheme> deregulation of the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Other" id="E15">
<type class="Localization"/>
<theme idref="T19"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a result of <clueType>translocation</clueType> <clueLoc>into the IgH locus</clueLoc>; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Other" id="E16">
<type class="Regulation"/>
<theme idref="E13"/>
<cause idref="E15"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a <clueType>result</clueType> <linkCause>of</linkCause> translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Other" id="E160">
<type class="Regulation"/>
<theme idref="E130"/>
<cause idref="E15"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a <clueType>result</clueType> <linkCause>of</linkCause> translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch recombination.</clue>
</event>
<event KT="Other" id="E17">
<type class="DNA_recombination"/>
<theme idref="T22"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a result of translocation into the IgH locus; and (3) it has been implicated in the mechanisms that control Ig gene class switch <clueType>recombination</clueType>.</clue>
</event>
<event KT="Fact" id="E18">
<type class="Regulation"/>
<theme idref="E17"/>
<cause idref="T13"/>
<clue>One of the latter elements, the IgH 3&apos; enhancer, is of particular interest: (1) it is B cell-specific and active only in late B cell development; (2) in rodent plasmacytomas and in some human Burkitt&apos;s lymphomas it is part of a locus control region (LCR) that is involved in deregulation of the c-myc oncogene as a result of translocation into the IgH locus; and (3) <corefCause>it</corefCause> has been implicated in the mechanisms that <clueType>control</clueType> Ig gene class switch recombination.</clue>
</event>
<sentence id="S4">We have used a <term id="T23" lex="somatic_cell_hybridization_approach" sem="Other">somatic cell hybridization approach</term> to genetically analyse regulation of the activity of the <term id="T24" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term>.</sentence>
<event KT="Investigation" id="E19" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="T24"/>
<clue>We have used <clueExperiment>a somatic cell hybridization approach</clueExperiment> <clueKT>to</clueKT> genetically <clueKT>analyse</clueKT> <clueType>regulation</clueType> <linkTheme>of</linkTheme> the activity of the IgH 3&apos; enhancer.</clue>
</event>
<sentence id="S5">When <term id="T25" lex="mouse_MPC11_plasmacytoma_cell" sem="Cell_cultured">mouse MPC11 plasmacytoma cells</term>, in which the <term id="T26" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term> is active, are fused with <term id="T27" lex="fibroblast" sem="Cell_natural">fibroblasts</term>, <term id="T28" lex="Ig_expression" sem="Other"><term id="A4" sem="Protein_family_or_group">Ig</term> expression</term> is extinguished at the level of transcription.</sentence>
<event KT="Fact" id="E20">
<type class="Positive_regulation"/>
<theme idref="T26"/>
<clue>When <clueLoc>mouse MPC11 plasmacytoma cells</clueLoc>, in which the IgH 3&apos; enhancer is <clueType>active</clueType>, are fused with fibroblasts, Ig expression is extinguished at the level of transcription.</clue>
</event>
<event KT="Other" id="E21">
<type class="Cellular_physiological_process"/>
<theme idref="T25"/>
<theme idref="T27"/>
<clue>When mouse MPC11 plasmacytoma cells, in which the IgH 3&apos; enhancer is active, are <clueType>fused</clueType> <linkTheme>with</linkTheme> fibroblasts, Ig expression is extinguished at the level of transcription.</clue>
</event>
<event KT="Other" id="E22">
<type class="Transcription"/>
<theme idref="A4"/>
<clue>When mouse MPC11 plasmacytoma cells, in which the IgH 3&apos; enhancer is active, are fused with fibroblasts, Ig <clueType>expression</clueType> is extinguished at the level of transcription.</clue>
</event>
<event KT="Fact" id="E23">
<type class="Negative_regulation"/>
<theme idref="E22"/>
<cause idref="E21"/>
<clue><linkCause>When</linkCause> mouse MPC11 plasmacytoma cells, in which the IgH 3&apos; enhancer is active, are fused with fibroblasts, Ig expression is <clueType>extinguished</clueType> at the level of transcription.</clue>
</event>
<sentence id="S6">Here we show that in a <term id="T29" lex="MPC11_plasmacytoma_x_fibroblast_environment" sem="Cell_cultured">MPC11 <term id="T30" lex="plasmacytoma_x_fibroblast_environment" sem="Cell_cultured">plasmacytoma x fibroblast environment</term></term>, the <term id="T31" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term> is transcriptionally inactive.</sentence>
<event KT="Analysis" id="E24">
<type class="Negative_regulation"/>
<theme idref="T31"/>
<clue>Here we <clueKT>show</clueKT> that <clueLoc>in a MPC11 plasmacytoma x fibroblast environment</clueLoc>, the IgH 3&apos; enhancer is transcriptionally <clueType>inactive</clueType>.</clue>
</event>
<sentence id="S7">Furthermore, we demonstrate that binding of several <term id="T32" lex="B_cell-specific_transcription_factor" sem="Protein_family_or_group">B cell-specific <term id="T33" lex="transcription_factor" sem="Protein_family_or_group">transcription factors</term></term>, essential for <term id="T34" lex="IgH_3&apos;_enhancer_activity" sem="Other"><term id="T35" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term> activity</term>, is lacking, which may explain <term id="T36" lex="3&apos;_enhancer_inactivity" sem="Other">3&apos; enhancer inactivity</term>, although the binding of <term id="A5" sem="Protein_molecule">repressors</term> cannot be excluded.</sentence>
<event KT="Other" id="E25">
<type class="Binding"/>
<theme idref="T32"/>
<clue>Furthermore, we demonstrate that <clueType>binding</clueType> <linkTheme>of</linkTheme> several B cell-specific transcription factors, essential for IgH 3&apos; enhancer activity, is lacking, which may explain 3&apos; enhancer inactivity, although the binding of repressors cannot be excluded.</clue>
</event>
<event KT="Other" id="E27">
<type class="Positive_regulation"/>
<theme idref="T35"/>
<cause idref="E25"/>
<clue>Furthermore, we demonstrate that binding of several B cell-specific transcription factors, <clueType>essential</clueType> <linkTheme>for</linkTheme> IgH 3&apos; enhancer activity, is lacking, which may explain 3&apos; enhancer inactivity, although the binding of repressors cannot be excluded.</clue>
</event>
<event KT="Analysis" id="E28">
<type class="Negative_regulation"/>
<theme idref="E25"/>
<clue>Furthermore, we <clueKT>demonstrate</clueKT> that binding of several B cell-specific transcription factors, essential for IgH 3&apos; enhancer activity, is <clueType>lacking</clueType>, which may explain 3&apos; enhancer inactivity, although the binding of repressors cannot be excluded.</clue>
</event>
<event CL="L1" KT="Analysis" id="E29" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="T35"/>
<cause idref="E28"/>
<clue>Furthermore, we demonstrate that binding of several B cell-specific transcription factors, essential for IgH 3&apos; enhancer activity, is lacking, which <clueCL>may</clueCL> <clueKT>explain</clueKT> <corefTheme>3&apos; enhancer</corefTheme> <clueType>inactivity</clueType>, although the binding of repressors cannot be excluded.</clue>
</event>
<event KT="Other" id="E30">
<type class="Binding"/>
<theme idref="A5"/>
<clue>Furthermore, we demonstrate that binding of several B cell-specific transcription factors, essential for IgH 3&apos; enhancer activity, is lacking, which may explain 3&apos; enhancer inactivity, although the <clueType>binding</clueType> <linkTheme>of</linkTheme> repressors cannot be excluded.</clue>
</event>
<event CL="L2" KT="Analysis" Polarity="Negative" assertion="non-exist" id="E31">
<type class="Negative_regulation"/>
<theme idref="E30"/>
<cause idref="E28"/>
<clue>Furthermore, we demonstrate that binding of several B cell-specific transcription factors, essential for IgH 3&apos; enhancer activity, is lacking, which may explain 3&apos; enhancer inactivity, although the binding of repressors <clueKT><clueCL>can</clueCL></clueKT><cluePolarity>not</cluePolarity> be <clueType>excluded</clueType>.</clue>
</event>
<sentence id="S8">Moreover, the high expression level of <term id="T37" lex="c-myc" sem="DNA_domain_or_region">c-myc</term>, characteristic of the parental <term id="T38" lex="MPC11_cell" sem="Cell_cultured">MPC11 cells</term> carrying the <term id="T39" lex="t(12;15)_translocation" sem="DNA_domain_or_region">t(12;15) translocation</term>, is down-regulated in the hybrids to that in unfused <term id="T40" lex="fibroblast" sem="Cell_natural">fibroblasts</term>.</sentence>
<event Manner="High" id="E32">
<type class="Gene_expression"/>
<theme idref="T37"/>
<clue>Moreover, the <clueManner>high</clueManner> <clueType>expression</clueType> level <linkTheme>of</linkTheme> c-myc, characteristic of the parental MPC11 cells carrying the t(12;15) translocation, is down-regulated in the hybrids to that in unfused fibroblasts.</clue>
</event>
<event id="E33">
<type class="Negative_regulation"/>
<theme idref="E32"/>
<clue>Moreover, the high expression level of c-myc, characteristic of the parental MPC11 cells carrying the t(12;15) translocation, is <clueType>down-regulated</clueType> <clueLoc>in the hybrids to that in unfused fibroblasts</clueLoc>.</clue>
</event>
<sentence id="S9">Therefore, inactivation of the <term id="T41" lex="IgH_3&apos;_enhancer" sem="DNA_domain_or_region">IgH 3&apos; enhancer</term> is a multifactorial process affecting several <term id="T42" lex="transcription_factor" sem="Protein_family_or_group">transcription factors</term> that control the cell-specific and developmental activity of the <term id="T43" lex="enhancer" sem="DNA_domain_or_region">enhancer</term>.</sentence>
<event KT="Other" id="E34">
<type class="Negative_regulation"/>
<theme idref="T41"/>
<clue>Therefore, <clueType>inactivation</clueType> <linkTheme>of</linkTheme> the IgH 3&apos; enhancer is a multifactorial process affecting several transcription factors that control the cell-specific and developmental activity of the enhancer.</clue>
</event>
<event KT="Analysis" id="E35">
<type class="Regulation"/>
<theme idref="T42"/>
<cause idref="E34"/>
<clue><clueKT>Therefore</clueKT>, inactivation of the IgH 3&apos; enhancer is a multifactorial process <clueType>affecting</clueType> several transcription factors that control the cell-specific and developmental activity of the enhancer.</clue>
</event>
<event KT="Other" id="E36">
<type class="Regulation"/>
<theme idref="T41"/>
<cause idref="T42"/>
<clue>Therefore, inactivation of the IgH 3&apos; enhancer is a multifactorial process affecting several transcription factors that <clueType>control</clueType> the cell-specific and developmental activity of <corefTheme>the enhancer</corefTheme>.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
